Amount Raised
$32 Million
Round Type
Series B
Menlo ParkBiotechnologyHealthcareDescription
Octave Bioscience, the developer of a fully integrated care management platform for multiple sclerosis (MS) and other neurodegenerative diseases, today announced the completion of a $32 million Series B financing. Northpond Ventures led the investment round with participation by Deerfield Management and Casdin Capital. All previous investors participated in the financing round, including the Blue Venture Fund, Echo Health Ventures, Section 32 and several private investors. This financing will allow the company to complete development of its novel measurement and management products and services, further expand clinical data, initiate early commercial activities and begin to serve neurologists, MS patients and health plans.
Quick answer
Octave Bioscience raised $32 Million in a Series B round, dated December 17, 2020. Octave Bioscience is based in Menlo Park, California, United States.
- How much did Octave Bioscience raise?
- Octave Bioscience raised $32 Million in a Series B round on December 17, 2020.
- What does Octave Bioscience do?
- Octave Bioscience, Inc. is a commercial growth stage precision medicine company pioneering biomarker-driven solutions for neurodegenerative diseases, with an initial focus on Multiple Sclerosis, and Parkinson’s Disease..
- Where is Octave Bioscience based and how big is it?
- Octave Bioscience is based in Menlo Park, California, United States. Fundz records about 83 employees.
- Who are the decision-makers at Octave Bioscience?
- Fundz holds 2 contacts at Octave Bioscience, including the Director. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Healthcare and Biotechnology around the same time
Companies in the same sectors as Octave Bioscience that raised within 45 days of this round, from Fundz verified event records.
- Pasithea Therapeutics Corp. raised $250K on January 29, 2021.
- Vita Therapeutics, Inc. raised $20M on January 29, 2021.
- Cancer Prevention Pharmaceuticals, Inc. raised $400K (Seed) on January 29, 2021.
- Endovia Health Sciences, Inc. raised $220K on January 27, 2021.
- Design Therapeutics, Inc. raised $125M (Series B) on January 27, 2021.
- Microbion Corp raised $2M (Seed) on January 25, 2021.
Who to call at Octave Bioscience, and when
A new round usually means Octave Bioscience is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Octave Bioscience raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Octave Bioscience, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Octave Bioscience. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Octave Bioscience raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansOctave Bioscience raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.